ReviewNutrition reviews2026
Metabolic Phenotypes, Genotypes, and Gut Microbiome Signatures in Obesity: Implications for Precision Nutrition Strategies in Type 2 Diabetes Prevention.
Review in Nutrition reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Sulforaphane and Broccoli-Derived Preparations in Obesity and Obesity-Related Metabolic Dysfunction: Mechanistic Insights, Preclinical Evidence, and Clinical Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Polyphenol-based modulation of the Glo1-Nrf2-RAGE axis in diabetes and neurodegeneration: mechanistic evidence, translational constraints, and critical appraisal.Frontiers in pharmacology · 2026Review
- Associations between the gut microbiome and diet, body composition, and glycemic profiles: a cross-sectionalFrontiers in nutrition · 2026Article
- Visceral fat area and visceral-to-subcutaneous fat ratio are more strongly associated with residual cholesterol than conventional anthropometric indices in adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Review
- Nutrigenomics meets multi-omics: integrating genetic, metabolic, and microbiome data for personalized nutrition strategies.Genes & nutrition · 2025Review
- Harnessing Metabolomics to Advance Nutrition-Based Therapeutics for Inflammation: A Systematic Review of Randomized Clinical Trials.Metabolites · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The worldwide prevalence of overweight and obesity has increased rapidly in the last decades. This rise has led to a surge in comorbidities such as type 2 diabetes (T2D), cardiometabolic diseases, and mental health issues. While general population-based nutrition guidelines have proven effective in reducing T2D incidence by 50%, a significant 30% of participants do not respond to these interventions. Precision nutrition (PN), tailored towards the metabolic phenotype (metabotype), genotype, or microbial characteristics, has shown promise in improving blood glucose control and cardiometabolic health compared with standard nutritional guidelines. This scoping review aims to discuss advancements in PN over the past decade, focusing on heterogeneity in response to dietary interventions aiming to prevent T2D and related cardiometabolic disease in overweight and obese individuals. A semi-systematic PubMed search with defined criteria was conducted to identify precision nutrition (PN) randomized clinical trials and related post-hoc analyses reporting cardiometabolic health outcomes. Numerous studies have shown actionable diet-host interactions, with intervention stratification based on genotype, gut microbiome, metabolome, lipidome, fasting glucose and insulin, postprandial glycemic response, tissue-specific insulin resistance, or combinations thereof. Many of these metabotypes, genotypes, and microbial signatures allow for accurate cardiometabolic outcome predictions and are actionable targets for future PN research. More recently, machine-learning methodologies in the form of postprandial response prediction models have increasingly been used in PN research. However, prospective evidence on effective PN strategies that may prevent the onset of T2D is currently limited. A mechanistic understanding of response and nonresponse in cardiometabolic outcome improvement is crucial in the development of novel phenotyping methodologies and prediction models in PN. These advancements could lead to more inclusive and effective PN strategies to prevent T2D and related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.